Skip to main content
. Author manuscript; available in PMC: 2021 Apr 28.
Published in final edited form as: Diabetes Obes Metab. 2020 Jul 5;22(10):1827–1836. doi: 10.1111/dom.14104

FIGURE 2.

FIGURE 2

TYK2 inhibitors revert IFNα-induced CXCL10 and MX1 but not HLA-ABC and CHOP expression in EndoC-βH1 cells. EndoC-βH1 cells were pretreated for 24 hours with IFNα (2000 U/mL). The TYK2 inhibitors (iA and iB for TYK2iA and B, respectively, 1 μM) were then added for an additional 24 hours in the continuous presence of IFNα. The mRNA expression of CXCL10 (A), MX1 (B), HLA-ABC (C) and CHOP (D) was analysed by RT-qPCR and the values were normalized by β-actin and then by cells treated with IFNα without TYK2 inhibitors, considered as 1. Results are mean ± SEM of six independent experiments. *P < .05, **P < .01 and ***P < .001 vs. control (CTL NT); †††P < .001 vs. CTL IFNα; one-way ANOVA